Somalogic Inks Deal With U of Oxford for SomaScan Platform; Plans CVD Dx Launch This Year | GenomeWeb

NEW YORK (GenomeWeb) – Somalogic notched another placement for its SomaScan assay platform, announcing this week that the University of Oxford would install a system as part of a larger collaboration between the two parties.

According to John Bell, professor of medicine at Oxford and chairman of the UK's Office for Strategic Coordination of Health Research, Oxford researchers will use the SomaScan platform for work on protein biomarkers for conditions including inflammatory diseases, Alzheimer's, and cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.